Ingestible Scouring Sponge Identifies Esophageal Abnormities
By HospiMedica International staff writers Posted on 12 Feb 2019 |
Image: An expandable polyurethane sphere helps detect esophageal cancer (Photo courtesy of CapNostics).
A minimally invasive esophageal cytology sampling device in the form of a small sponge can aid early diagnosis of Barrett's esophagus (BE) and esophageal cancer in high-risk patients.
The CapNostics (Doylestown, PA, USA) EsophaCap is a swallowable device made of medical grade foam compressed into an ingestible capsule that is designed for deployment within 10 minutes. Once swallowed, the gelatin coating on the capsule dissolves in under three minutes, causing the polyurethane sponge, which is attached to a string, to expand into a sphere two centimeters in diameter. The string is then gently pulled back through the mouth; as the sponge makes its way up, it collects genetic material along the length and breadth of the esophagus.
When the sponge reaches the top of the esophagus it is withdrawn, laden with DNA material that is subsequently extracted using a technique known as methylation on beads (MOB). The beads bind to the DNA, which can be easily collected and subsequently analyzed by a biomarker panel so as to identify the four methylation biomarkers that appear to best predict which patients with BE might progress to neoplasia. In a study published on January 22, 2019, in Clinical Cancer Research, EsophaCap showed a diagnostic accuracy of 86.7%, a sensitivity of 78.6%, and a specificity of 92.8% for BE detection.
“Early detection is the whole ballgame when it comes to esophageal cancer. This novel sponge device can be administered by anyone with minimal training, ideally in any physician's office, where the procedure could be routinely performed,” said senior study author Professor Stephen Meltzer, MD, of Johns Hopkins University (JHU, Baltimore, MD, USA). “This is cheaper, easier and safer than endoscopy. Nor does the EsophaCap have to be protected against contamination from DNA material as the device passes through normal esophageal tissue in smokers.”
Barrett's esophagus refers to an abnormal change (metaplasia) in the cells of the lower portion of the esophagus, when the normal squamous epithelium lining is replaced by goblet cells, which are usually found lower in the gastroitestinal tract. The medical significance of BE is its strong association with esophageal adenocarcinoma, a particularly lethal form of cancer.
Related Links:
CapNostics
The CapNostics (Doylestown, PA, USA) EsophaCap is a swallowable device made of medical grade foam compressed into an ingestible capsule that is designed for deployment within 10 minutes. Once swallowed, the gelatin coating on the capsule dissolves in under three minutes, causing the polyurethane sponge, which is attached to a string, to expand into a sphere two centimeters in diameter. The string is then gently pulled back through the mouth; as the sponge makes its way up, it collects genetic material along the length and breadth of the esophagus.
When the sponge reaches the top of the esophagus it is withdrawn, laden with DNA material that is subsequently extracted using a technique known as methylation on beads (MOB). The beads bind to the DNA, which can be easily collected and subsequently analyzed by a biomarker panel so as to identify the four methylation biomarkers that appear to best predict which patients with BE might progress to neoplasia. In a study published on January 22, 2019, in Clinical Cancer Research, EsophaCap showed a diagnostic accuracy of 86.7%, a sensitivity of 78.6%, and a specificity of 92.8% for BE detection.
“Early detection is the whole ballgame when it comes to esophageal cancer. This novel sponge device can be administered by anyone with minimal training, ideally in any physician's office, where the procedure could be routinely performed,” said senior study author Professor Stephen Meltzer, MD, of Johns Hopkins University (JHU, Baltimore, MD, USA). “This is cheaper, easier and safer than endoscopy. Nor does the EsophaCap have to be protected against contamination from DNA material as the device passes through normal esophageal tissue in smokers.”
Barrett's esophagus refers to an abnormal change (metaplasia) in the cells of the lower portion of the esophagus, when the normal squamous epithelium lining is replaced by goblet cells, which are usually found lower in the gastroitestinal tract. The medical significance of BE is its strong association with esophageal adenocarcinoma, a particularly lethal form of cancer.
Related Links:
CapNostics
Latest Critical Care News
- AI to Improved Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia